Outlook Therapeutics (OTLK) investor relations material

Executive summary

• FDA approval of LYTENAVA marks it as the only FDA-approved ophthalmic bevacizumab for wet AMD in the U.S., expanding commercial opportunities and addressing a significant unmet need in retina care.

• The company is focused on converting this regulatory achievement into a successful and sustainable U.S. commercial launch, leveraging a highly concentrated retina market and a differentiated product profile, with launch planned before the end of calendar 2026.

• LYTENAVA is positioned to address the widespread use of off-label repackaged bevacizumab, offering physicians a familiar molecule with FDA oversight and product consistency.

• Commercial strategy centers on targeted engagement with retina specialists, robust market access, and reimbursement infrastructure, aiming for a measured, high-quality market entry.

• European commercialization continues, with launches in Germany, Austria, and the U.K., and expansion planned for the Netherlands and Switzerland.

Financial highlights

• Adjusted net loss attributable to common stockholders for Q3 FY2026 was $10.9 million ($0.09 per share), improved from $15.8 million ($0.44 per share) in Q3 FY2025.

• Net loss attributable to common stockholders for Q3 FY2026 was $20.3 million ($0.15 per share), compared to $20.2 million ($0.55 per share) in Q3 FY2025.

• European revenue improved, with a 46% increase in unit sales over the previous quarter; Q4 unit sales are expected to match Q3 despite seasonal slowdown.

• Cash and cash equivalents stood at $11.2 million as of June 30, 2026, not including $51.1 million in net proceeds from a $55 million public offering in August 2026.

• Adjustments to net loss exclude losses from changes in fair value of promissory notes, warrant liability, and extinguishment of debt.

Outlook and guidance

• Projected U.S. peak annual sales for LYTENAVA are over $500 million by 2030, with potential upside of nearly $300 million if compounded supply is disrupted.

• First 12 months post-U.S. launch, total net revenue is expected between $50 million and $75 million, with Europe contributing 10%-15%.

• Launch ramp is expected to be progressive, with 10% of first-year revenue in the first three months and 50% in the fourth quarter post-launch, driven by anticipated permanent J-code in April 2027.

• Application for a permanent HCPCS code to support reimbursement is planned by October 1, 2026.

• Quarterly SG&A expenses are expected to double by end of 2026, with a further 10% increase in 2027; R&D expenses to remain steady as prefilled syringe development continues.